Payment overview · 2025
General Payments
$237.74
10 reported records · 6 companies
Healthcare provider profile · identity verified
Mandy Louise Maneval, MD
Allopathic & Osteopathic Physicians|Family Medicine · MIFFLINTOWN, PA · NPI 1407064207
Verified facts
What the public records show
CMS Open Payments records show Mandy Louise Maneval, MD received $237.74 in general payments during 2025 across 10 reported records.
Dexcom, Inc. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $78.25 | 32.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.73 | 24.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $31.40 | 13.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.16 | 12.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.74 | 10.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.46 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $237.74 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $78.25 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.73 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.73 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $31.40 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 93 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 300 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 292 | 68 |
| Lisinopril | Lisinopril | 266 | 66 |
| Omeprazole | Omeprazole | 226 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 158 | 35 |
| Metformin Hcl | Metformin Hcl | 146 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 30 |
| Furosemide | Furosemide | 112 | 33 |
| Losartan Potassium | Losartan Potassium | 110 | 28 |
| Gabapentin | Gabapentin | 108 | 30 |
| Sertraline Hcl | Sertraline Hcl | 99 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 22 |
| Eliquis | Apixaban | 93 | 15 |
| Metformin Hcl Er | Metformin Hcl | 88 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 13 |
| Montelukast Sodium | Montelukast Sodium | 79 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 16 |
| Ozempic | Semaglutide | 68 | 14 |
| Meloxicam | Meloxicam | 66 | 19 |
| Trazodone Hcl | Trazodone Hcl | 65 | 18 |
| Lorazepam | Lorazepam | 62 | 24 |
| Simvastatin | Simvastatin | 62 | 17 |
| Potassium Chloride | Potassium Chloride | 61 | 11 |
| Famotidine | Famotidine | 59 | 12 |
| Jardiance | Empagliflozin | 59 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 19 |
| Finasteride | Finasteride | 53 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 15 |
| Pregabalin | Pregabalin | 47 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 12 |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Allopurinol | Allopurinol | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 15 |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 12 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Prednisone | Prednisone | 29 | 11 |
| Carvedilol | Carvedilol | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | 11 |
| Baclofen | Baclofen | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 12 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Cimetidine | Cimetidine | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $237.74 · 10 records | Dexcom, Inc. | Dexcom G6 Transmitter, ELIQUIS, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error